busulfan has been researched along with Seizures in 41 studies
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Anticonvulsant administration is the standard of care for prevention of busulfan-induced seizures (BIS) in hematopoietic stem cell transplantation (HSCT)." | 7.91 | Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation. ( Fukuda, T; Hashimoto, H; Inamoto, Y; Ito, A; Kim, SW; Koido, K; Kurosawa, S; Nakashima, T; Nishibuchi, Y; Tanaka, T; Terakado, H, 2019) |
| "Busulfan is used as a conditioning regimen for hematopoietic stem cell transplantation and is known to cause seizures as a side effect." | 7.88 | Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients. ( Akiyama, K; Enami, T; Fukaya, M; Ikeda, T; Kume, T; Shiki, I; Shino, M; Tatara, R, 2018) |
| "Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures." | 7.85 | Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017) |
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 7.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| "Characteristics of ideal seizure prophylaxis include lack of overlapping toxicity with the conditioning regimen, lack of interference with engraftment of donor cells, and minimal potential for pharmacokinetic drug interactions." | 6.44 | Optimal prevention of seizures induced by high-dose busulfan. ( Anderson, GD; Bubalo, JS; Eberly, AL; McCune, JS, 2008) |
| "Background Antiseizure prophylaxis is recommended when high-dose of busulfan is given as part of the conditioning regimens in the allogenic hematopoietic stem cell transplant." | 5.56 | Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. ( Aguilera-Jiménez, V; Chaguaceda, C; Gutierrez, G; Riu, G; Roura, J, 2020) |
| " Administration of phenytoin or newer alternative antiepileptic medications (AEMs) prevents seizures caused by BU." | 5.30 | Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. ( Aljurf, M; Beitinjaneh, A; Bo-Subait, K; Bubalo, J; Cahn, JY; Cerny, J; Chhabra, S; Cumpston, A; Dupuis, LL; Krem, MM; Lazarus, HM; Marks, DI; Martin, PJ; Maziarz, RT; McCune, JS; Mineishi, S; Norkin, M; Pasquini, M; Prestidge, T; Wang, T, 2019) |
| "We emphasize that convulsions are not infrequent side effect of conditioning regimens including high dose busulfan, and efficient anticonvulsant prophylactic regimens should be used." | 5.28 | High dose busulfan and seizures. ( Berberana, M; De La Camara, R; Fernandez-Rañada, JM; Figuera, A; Tomas, JF, 1991) |
| " The data were evaluated to compare the incidence of busulfan-induced seizures in HSCT patients receiving either phenytoin or levetiracetam and to determine the impact of drug-drug interactions on treatment outcomes/adverse events." | 4.02 | Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution. ( Garrity, L; Hughes, K; Lane, A; Nelson, AS; Teusink-Cross, A, 2021) |
| " We retrospectively assessed the prophylactic efficacy and safety of levetiracetam and clonazepam against busulfan-induced seizures between 2013 and 2018." | 3.96 | Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. ( Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Shirai, R; Terashima, K; Tomizawa, D; Tsujimoto, SI; Uchiyama, T; Utano, T, 2020) |
| "Anticonvulsant administration is the standard of care for prevention of busulfan-induced seizures (BIS) in hematopoietic stem cell transplantation (HSCT)." | 3.91 | Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation. ( Fukuda, T; Hashimoto, H; Inamoto, Y; Ito, A; Kim, SW; Koido, K; Kurosawa, S; Nakashima, T; Nishibuchi, Y; Tanaka, T; Terakado, H, 2019) |
| "Busulfan is used as a conditioning regimen for hematopoietic stem cell transplantation and is known to cause seizures as a side effect." | 3.88 | Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients. ( Akiyama, K; Enami, T; Fukaya, M; Ikeda, T; Kume, T; Shiki, I; Shino, M; Tatara, R, 2018) |
| "Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures." | 3.85 | Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017) |
| "Due to their favorable toxicity profile and lack of interactions, benzodiazepines have been proposed as prophylaxis of busulfan induced seizures." | 3.79 | Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. ( Blanquer, M; Diaz-Carrasco, MS; Moraleda, JM; Olmos, R; Sánchez-Salinas, A; Velasco, J, 2013) |
| "At our Institute, during the last decade, the incidence of hepatic veno-occlusive disease (HVOD) appears to be on the increase among pediatric patients treated with BU-thiotepa (BU-TTP)-conditioning regimen." | 3.74 | Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. ( Amoroso, L; Benhamou, E; Cacchione, A; Couanet, DV; Hartmann, O; LeMaitre, A; Simonnard, N, 2008) |
| "Except for three studies, no seizure had occurred in patients who had received LEV." | 3.01 | Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence. ( Hadjibabaie, M; Honarmand, H; Kiumarsi, A; Rostami, T; Shahrami, B; Tavajohi, R, 2023) |
| " Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis." | 2.75 | Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. ( Bacigalupo, A; Buzyn, A; Cahn, JY; Carreras, E; Kröger, N; Puozzo, C; Sanz, G; Vernant, JP, 2010) |
| "Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis." | 2.70 | Lorazepam for seizure prophylaxis during high-dose busulfan administration. ( Chan, KW; Choroszy, M; Koontz, S; Mullen, CA; Slopis, J; Tran, H; Worth, LL, 2002) |
| "Five of 6 patients developing seizures received anticonvulsant and supportive treatment with resolution of neurologic abnormalities." | 2.68 | Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. ( Bernaudin, F; Bunin, N; Johnson, FL; Lenarsky, C; Ohene-Frempong, K; Powars, D; Souillet, G; Sullivan, KM; Vannier, JP; Walters, MC, 1995) |
| "Characteristics of ideal seizure prophylaxis include lack of overlapping toxicity with the conditioning regimen, lack of interference with engraftment of donor cells, and minimal potential for pharmacokinetic drug interactions." | 2.44 | Optimal prevention of seizures induced by high-dose busulfan. ( Anderson, GD; Bubalo, JS; Eberly, AL; McCune, JS, 2008) |
| "Busulfan is an effective myeloablative conditioning agent for HSCT." | 2.43 | Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan. ( Barnes, YJ; Fisher, VL; Nuss, SL, 2006) |
| "To evaluate the toxic extramedullary morbidity of the conditioning treatment with BuCy for BMT, as well as the usefulness of pentoxyphyllin (PTX) and methylprednisolone (MP) in the prophylaxis of mucositis." | 2.39 | [Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning]. ( Maldonado, J; Pascual, MJ, 1995) |
| "Background Antiseizure prophylaxis is recommended when high-dose of busulfan is given as part of the conditioning regimens in the allogenic hematopoietic stem cell transplant." | 1.56 | Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. ( Aguilera-Jiménez, V; Chaguaceda, C; Gutierrez, G; Riu, G; Roura, J, 2020) |
| "The incidence of seizures was 0." | 1.43 | Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation. ( Leon-Rodriguez, E; Rivera-Franco, MM, 2016) |
| "Hence, seizure prophylaxis is routinely utilized during BU administration for stem cell transplantation (SCT)." | 1.40 | Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. ( Aricò, M; Caselli, D; Cesaro, S; Cicalese, MP; Faraci, M; Lo Nigro, L; Locatelli, F; Longoni, D; Maximova, N; Menconi, MC; Nesi, F; Paolicchi, O; Podda, M; Prete, A; Ripaldi, M; Rosati, A; Santarone, S; Ziino, O, 2014) |
| "Levetiracetam was well tolerated and was efficacious in preventing seizures." | 1.38 | Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. ( Bajwa, RP; Gross, TG; Pai, V; Skeens, M; Soni, S; Termuhlen, AM, 2012) |
| "Oral lorazepam was tolerated by the patients, but all patients needed dose reduction due to some adverse effects." | 1.36 | Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. ( Amini, M; Ghavamzadeh, A; Hadjibabaie, M; Hamedani, R; Hamidieh, AA; Sadrai, S, 2010) |
| "Busulfan was eliminated by a first-order process." | 1.33 | Accidental busulfan overdose during conditioning for stem cell transplantation. ( Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Freund, M; Jenke, A; Renner, UD; Schleyer, E; Schuler, U; Wilhelm, S, 2005) |
| "A 21-year-old woman with acute lymphoblastic leukemia underwent bone marrow transplantation (BMT)." | 1.32 | Busulfan neurotoxicity and EEG abnormalities: a case report. ( Bonifazi, F; Cirignotta, F; Guarino, M; La Morgia, C; Mondini, S, 2004) |
| "The aims of the present study were (1) to investigate and quantify the pharmacokinetics, including inter-occasion variability and covariate relationships, of busulphan in BMT patients and (2) to develop a user-friendly initial dosing and therapeutic drug monitoring (TDM) strategy for the treatment of those patients with busulphan." | 1.31 | Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. ( Bekassy, A; Hassan, M; Hassan, Z; Jonsson, EN; Karlsson, MO; Ljungman, P; Nilsson, C; Oberg, G; Ringden, O; Sandström, M, 2001) |
| "Eighteen patients with poor risk Ewing's sarcoma (including 11 patients with metastatic disease at presentation) received consolidation therapy of busulphan and melphalan with autologous stem cell rescue." | 1.30 | High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. ( Ashley, S; Atra, A; Calvagna, V; Pinkerton, CR; Shankar, AG; Shepherd, V; Souhami, RL; Whelan, JS, 1997) |
| "We emphasize that convulsions are not infrequent side effect of conditioning regimens including high dose busulfan, and efficient anticonvulsant prophylactic regimens should be used." | 1.28 | High dose busulfan and seizures. ( Berberana, M; De La Camara, R; Fernandez-Rañada, JM; Figuera, A; Tomas, JF, 1991) |
| "Busulfan was given p." | 1.28 | Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. ( Benhamou, E; Brugières, L; Challine, D; Deroussent, A; Gouyette, A; Hartmann, O; Kalifa, C; Lemerle, J; Valteau-Couanet, D; Vassal, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (12.20) | 18.7374 |
| 1990's | 10 (24.39) | 18.2507 |
| 2000's | 10 (24.39) | 29.6817 |
| 2010's | 12 (29.27) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Tavajohi, R | 1 |
| Shahrami, B | 1 |
| Rostami, T | 1 |
| Kiumarsi, A | 1 |
| Honarmand, H | 1 |
| Hadjibabaie, M | 2 |
| Tsujimoto, SI | 1 |
| Shirai, R | 1 |
| Utano, T | 1 |
| Osumi, T | 1 |
| Matsumoto, K | 2 |
| Shioda, Y | 1 |
| Kiyotani, C | 1 |
| Uchiyama, T | 1 |
| Deguchi, T | 1 |
| Terashima, K | 1 |
| Tomizawa, D | 1 |
| Kato, M | 1 |
| Chaguaceda, C | 1 |
| Aguilera-Jiménez, V | 1 |
| Gutierrez, G | 1 |
| Roura, J | 1 |
| Riu, G | 1 |
| Hughes, K | 1 |
| Garrity, L | 1 |
| Nelson, AS | 1 |
| Lane, A | 1 |
| Teusink-Cross, A | 1 |
| Akiyama, K | 1 |
| Kume, T | 1 |
| Fukaya, M | 1 |
| Shiki, I | 1 |
| Enami, T | 1 |
| Tatara, R | 1 |
| Shino, M | 1 |
| Ikeda, T | 1 |
| McCune, JS | 3 |
| Wang, T | 1 |
| Bo-Subait, K | 1 |
| Aljurf, M | 1 |
| Beitinjaneh, A | 1 |
| Bubalo, J | 1 |
| Cahn, JY | 3 |
| Cerny, J | 1 |
| Chhabra, S | 1 |
| Cumpston, A | 1 |
| Dupuis, LL | 1 |
| Lazarus, HM | 1 |
| Marks, DI | 1 |
| Maziarz, RT | 1 |
| Norkin, M | 1 |
| Prestidge, T | 1 |
| Mineishi, S | 2 |
| Krem, MM | 1 |
| Pasquini, M | 1 |
| Martin, PJ | 1 |
| Nakashima, T | 1 |
| Tanaka, T | 1 |
| Koido, K | 1 |
| Nishibuchi, Y | 1 |
| Hashimoto, H | 1 |
| Ito, A | 1 |
| Inamoto, Y | 1 |
| Kurosawa, S | 1 |
| Kim, SW | 1 |
| Fukuda, T | 1 |
| Terakado, H | 1 |
| Diaz-Carrasco, MS | 1 |
| Olmos, R | 1 |
| Blanquer, M | 1 |
| Velasco, J | 1 |
| Sánchez-Salinas, A | 1 |
| Moraleda, JM | 1 |
| Caselli, D | 2 |
| Rosati, A | 1 |
| Faraci, M | 1 |
| Podda, M | 1 |
| Ripaldi, M | 1 |
| Longoni, D | 1 |
| Cesaro, S | 1 |
| Lo Nigro, L | 1 |
| Paolicchi, O | 1 |
| Maximova, N | 1 |
| Menconi, MC | 1 |
| Ziino, O | 2 |
| Cicalese, MP | 1 |
| Santarone, S | 1 |
| Nesi, F | 1 |
| Aricò, M | 2 |
| Locatelli, F | 1 |
| Prete, A | 1 |
| Pasquini, MC | 1 |
| Le-Rademacher, J | 1 |
| Zhu, X | 1 |
| Artz, A | 1 |
| DiPersio, J | 1 |
| Fernandez, HF | 1 |
| Kamishohara, M | 1 |
| Mehta, J | 1 |
| Nakamura, Y | 1 |
| Ratanatharathorn, V | 1 |
| Sobecks, R | 1 |
| Burkart, J | 1 |
| Bredeson, C | 1 |
| Floeter, AE | 1 |
| Leon-Rodriguez, E | 1 |
| Rivera-Franco, MM | 1 |
| Cacchione, A | 1 |
| LeMaitre, A | 1 |
| Couanet, DV | 1 |
| Benhamou, E | 3 |
| Amoroso, L | 1 |
| Simonnard, N | 1 |
| Hartmann, O | 3 |
| Eberly, AL | 1 |
| Anderson, GD | 1 |
| Bubalo, JS | 1 |
| Hamidieh, AA | 1 |
| Hamedani, R | 1 |
| Amini, M | 1 |
| Sadrai, S | 1 |
| Ghavamzadeh, A | 1 |
| Carreras, E | 1 |
| Puozzo, C | 1 |
| Kröger, N | 1 |
| Sanz, G | 1 |
| Buzyn, A | 1 |
| Bacigalupo, A | 1 |
| Vernant, JP | 1 |
| Soni, S | 1 |
| Skeens, M | 1 |
| Termuhlen, AM | 1 |
| Bajwa, RP | 1 |
| Gross, TG | 1 |
| Pai, V | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Gomez-Almaguer, D | 1 |
| Steensma, DP | 1 |
| La Morgia, C | 1 |
| Mondini, S | 1 |
| Guarino, M | 1 |
| Bonifazi, F | 1 |
| Cirignotta, F | 1 |
| Jenke, A | 1 |
| Freiberg-Richter, J | 1 |
| Wilhelm, S | 1 |
| Freund, M | 1 |
| Renner, UD | 1 |
| Bornhäuser, M | 1 |
| Schleyer, E | 1 |
| Ehninger, G | 1 |
| Schuler, U | 1 |
| Sherry, JH | 1 |
| Bechtel, T | 1 |
| Fisher, VL | 1 |
| Barnes, YJ | 1 |
| Nuss, SL | 1 |
| Bartoli, A | 1 |
| Santangelo, G | 1 |
| Vanadia, F | 1 |
| Marcus, RE | 1 |
| Goldman, JM | 1 |
| Schwarer, AP | 1 |
| Opat, SS | 1 |
| Watson, AL | 1 |
| Cole-Sinclair, MF | 1 |
| Pascual, MJ | 1 |
| Maldonado, J | 1 |
| Walters, MC | 1 |
| Sullivan, KM | 1 |
| Bernaudin, F | 1 |
| Souillet, G | 1 |
| Vannier, JP | 1 |
| Johnson, FL | 1 |
| Lenarsky, C | 1 |
| Powars, D | 1 |
| Bunin, N | 1 |
| Ohene-Frempong, K | 1 |
| Hassan, M | 2 |
| Oberg, G | 2 |
| Björkholm, M | 1 |
| Wallin, I | 1 |
| Lindgren, M | 1 |
| Erer, B | 1 |
| Polchi, P | 1 |
| Lucarelli, G | 1 |
| Angelucci, E | 1 |
| Baronciani, D | 1 |
| Galimberti, M | 1 |
| Giardini, C | 1 |
| Gaziev, D | 1 |
| Maiello, A | 1 |
| Atra, A | 1 |
| Whelan, JS | 1 |
| Calvagna, V | 1 |
| Shankar, AG | 1 |
| Ashley, S | 1 |
| Shepherd, V | 1 |
| Souhami, RL | 1 |
| Pinkerton, CR | 1 |
| Sandström, M | 1 |
| Karlsson, MO | 1 |
| Ljungman, P | 1 |
| Hassan, Z | 1 |
| Jonsson, EN | 1 |
| Nilsson, C | 1 |
| Ringden, O | 1 |
| Bekassy, A | 1 |
| Kami, M | 1 |
| Hamaki, T | 1 |
| Maruta, Y | 1 |
| Miyakoshi, S | 1 |
| Mutou, Y | 1 |
| Chan, KW | 1 |
| Mullen, CA | 1 |
| Worth, LL | 1 |
| Choroszy, M | 1 |
| Koontz, S | 1 |
| Tran, H | 1 |
| Slopis, J | 1 |
| Tiberghien, P | 1 |
| Flesch, M | 1 |
| Paintaud, G | 1 |
| Ghany, AM | 1 |
| Tutschka, PJ | 1 |
| McGhee, RB | 1 |
| Avalos, BR | 1 |
| Cunningham, I | 1 |
| Kapoor, N | 1 |
| Copelan, EA | 1 |
| De La Camara, R | 1 |
| Tomas, JF | 1 |
| Figuera, A | 1 |
| Berberana, M | 1 |
| Fernandez-Rañada, JM | 1 |
| Vassal, G | 1 |
| Deroussent, A | 1 |
| Challine, D | 1 |
| Valteau-Couanet, D | 1 |
| Brugières, L | 1 |
| Kalifa, C | 2 |
| Gouyette, A | 1 |
| Lemerle, J | 2 |
| Grigg, AP | 1 |
| Shepherd, JD | 1 |
| Phillips, GL | 1 |
| Sureda, A | 1 |
| Pérez de Oteyza, J | 1 |
| García Laraña, J | 1 |
| Odriozola, J | 1 |
| Hugh-Jones, K | 1 |
| Shaw, PJ | 1 |
| Beaujean, F | 1 |
| Pico, JL | 1 |
| Patte, C | 1 |
| Flamant, F | 1 |
4 reviews available for busulfan and Seizures
| Article | Year |
|---|---|
Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence.
Topics: Adult; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Levetiracetam; Prospective | 2023 |
Optimal prevention of seizures induced by high-dose busulfan.
Topics: Alkylating Agents; Animals; Anticonvulsants; Benzodiazepines; Busulfan; Dose-Response Relationship, | 2008 |
Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
Topics: Administration, Oral; Adult; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; Dr | 2006 |
[Extramedullary toxicity in bone marrow transplantation using busulfan and cyclophosphamide conditioning].
Topics: Adolescent; Adult; Anemia, Refractory, with Excess of Blasts; Arrhythmias, Cardiac; Bone Marrow Tran | 1995 |
5 trials available for busulfan and Seizures
| Article | Year |
|---|---|
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.
Topics: Adolescent; Adult; Aged; Allografts; Anticonvulsants; Busulfan; Child; Child, Preschool; Cyclophosph | 2019 |
Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
Topics: Adolescent; Adult; Alkylating Agents; Anticonvulsants; Busulfan; Clonazepam; Cyclophosphamide; Drug | 2010 |
Clobazam for seizure prophylaxis during busulfan chemotherapy.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Antineoplastic Agents, Alkylating; Benzodiazepines; B | 1995 |
Neurologic complications after allogeneic marrow transplantation for sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Anticonvulsants; Antilymphocyte Serum; Bone Marrow Transplan | 1995 |
Lorazepam for seizure prophylaxis during high-dose busulfan administration.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2002 |
32 other studies available for busulfan and Seizures
| Article | Year |
|---|---|
Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Clonazepam; Female; Hematopoietic Stem Cell Transplan | 2020 |
Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant.
Topics: Adult; Anticonvulsants; Busulfan; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell | 2020 |
Comparison of levetiracetam versus phenytoin/fosphenytoin for busulfan seizure prophylaxis at a pediatric institution.
Topics: Adolescent; Adult; Anticonvulsants; Busulfan; Child; Child, Preschool; Drug Administration Schedule; | 2021 |
Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients.
Topics: Administration, Intravenous; Anticonvulsants; Busulfan; Female; Hematopoietic Stem Cell Transplantat | 2018 |
Comparison of valproate and levetiracetam for the prevention of busulfan-induced seizures in hematopoietic stem cell transplantation.
Topics: Adult; Aged; Anticonvulsants; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Imm | 2019 |
Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anticonvulsants; Busulfan; Clonazepam; Dose-Re | 2013 |
Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Female; Hem | 2014 |
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool | 2016 |
Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.
Topics: Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoiet | 2017 |
Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.
Topics: Adolescent; Adult; Alkylating Agents; Busulfan; Female; Humans; Incidence; Male; Middle Aged; Myeloa | 2016 |
Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Busulfan; Carboplatin; Child; Child, Preschool; | 2008 |
Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Dose-Response | 2010 |
Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Anticonvulsants; Busulfan; Child; Child, Preschool; Hematopoietic Stem Cell Trans | 2012 |
Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.
Topics: Administration, Oral; Anticonvulsants; Antineoplastic Agents, Alkylating; Busulfan; Dose-Response Re | 2012 |
Busulfan neurotoxicity and EEG abnormalities: a case report.
Topics: Acute Disease; Adult; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Electroencephalograp | 2004 |
Accidental busulfan overdose during conditioning for stem cell transplantation.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Drug Overdose; Female; Humans; Male; Medical Erro | 2005 |
Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Topics: Anticonvulsants; Bone Marrow Transplantation; Busulfan; Epilepsy; Humans; Phenytoin; Seizures; Thera | 2005 |
Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan.
Topics: Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Humans; Infant; Infusions, Intraveno | 2008 |
Convulsions due to high-dose busulphan.
Topics: Adult; Busulfan; Female; Humans; Leukemia, Myeloid; Male; Seizures | 1984 |
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Diazepam; Drug Interactions | 1993 |
CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Anticonvulsants; beta-Thalassemia; Blood | 1996 |
High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 1997 |
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Area Un | 2001 |
Limitations of oral busulfan in preparative regimen before hematopoietic stem-cell transplantation.
Topics: Administration, Oral; Adult; Alkylating Agents; Anticonvulsants; Busulfan; Headache; Hematopoietic S | 2002 |
More on high-dose busulfan and seizure prophylaxis.
Topics: Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Epilepsy; Female; Humans; Leukemi | 1992 |
Cyclosporine-associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Brain; Busulfan; Cyclophosphamide; Cyclosporins; Fem | 1991 |
High dose busulfan and seizures.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Dose-Response Relationship, Drug; Female; Graft Reject | 1991 |
Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Drug Evaluation; Humans; Infant; Neoplasms; Seizures | 1990 |
Busulphan and phenytoin.
Topics: Adult; Busulfan; Humans; Phenytoin; Seizures | 1989 |
High-dose busulfan and seizures.
Topics: Adolescent; Busulfan; Humans; Male; Seizures | 1989 |
No convulsions in children on high-dose busulphan.
Topics: Adolescent; Busulfan; Child; Child, Preschool; Humans; Seizures | 1985 |
High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C | 1986 |